1. Home
  2. IMMR vs FULC Comparison

IMMR vs FULC Comparison

Compare IMMR & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immersion Corporation

IMMR

Immersion Corporation

N/A

Current Price

$7.17

Market Cap

241.4M

Sector

Technology

ML Signal

N/A

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

N/A

Current Price

$3.70

Market Cap

285.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IMMR
FULC
Founded
1993
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Computer peripheral equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
241.4M
285.4M
IPO Year
1999
2019

Fundamental Metrics

Financial Performance
Metric
IMMR
FULC
Price
$7.17
$3.70
Analyst Decision
Hold
Analyst Count
0
5
Target Price
N/A
★ $3.67
AVG Volume (30 Days)
377.5K
★ 1.3M
Earning Date
09-14-2026
11-10-2026
Dividend Yield
★ 4.11%
N/A
EPS Growth
★ N/A
N/A
EPS
★ 0.17
N/A
Revenue
★ $35,013,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$42.76
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.25
$2.83
52 Week High
$8.05
$15.74

Technical Indicators

Market Signals
Indicator
IMMR
FULC
Relative Strength Index (RSI) 47.53 48.25
Support Level $7.03 $3.62
Resistance Level $7.64 $3.91
Average True Range (ATR) 0.17 0.07
MACD 0.01 0.01
Stochastic Oscillator 53.68 45.45

Price Performance

Historical Comparison
IMMR
FULC

About IMMR Immersion Corporation

Immersion Corp is a licensing company focused on the acceleration, and scaling, through licensing, of haptic technologies that allow people to use sense of touch to engage with products and experience the digital world around them. Its patents cover a wide range of digital technologies and ways in which touch-related technology can be incorporated into and between hardware products and components, systems software, application software, and digital content. It operates in two operating segments: Immersion and Barnes & Noble Education. The majority of revenue is derived from Barnes & Noble Education segment which is a contract operator of physical and virtual bookstores for college and university campuses and K-12 institutions across the United States.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: